Are responses to therapy of metastasized malignant melanoma reflected by decreasing serum values of S100β or melanoma inhibitory activity (MIA)?

Melanoma Research

Volumn 11, Issue 3, 2001, Pages 291-296

  Deichmann, M ^a   Benner, A ^a   Kuner, N ^a   Wacker, J ^a   Waldmann, V ^a   Naher H ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

C reactive protein (CRP); Lactate dehydrogenase (LDH); Melanoma; Melanoma inhibitory activity (MIA); S100 ; Tumour marker

Indexed keywords

C REACTIVE PROTEIN; LACTATE DEHYDROGENASE; MELANOMA INHIBITORY ACTIVITY; PROTEIN S 100; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; DIAGNOSTIC VALUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ADULT; AGED; AREA UNDER CURVE; CALCIUM-BINDING PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX PROTEINS; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; L-LACTATE DEHYDROGENASE; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NERVE GROWTH FACTORS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; ROC CURVE; S100 PROTEINS; TIME FACTORS;

EID: 0034960032     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200106000-00011     Document Type: Article

References (28)

1. Particle counting immunoassay of S100 protein in serum, possible relevance in tumors and ischemic disorders of the central nervous system
2. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma
3. MIA serum levels as a detection and monitoring system of malignant melanoma
4. Clinical significance of serum S100 in metastatic malignant melanoma
5. Serum S100, a marker for disease monitoring in metastatic melanoma
6. S100β protein in serum, a tumour marker in malignant melanoma, current state of knowledge and clinical experience
7. S100 protein serum levels in cutaneous malignant melanoma
8. S100β protein detection is a significant prognostic factor in metastatic melanoma
9. Prognostic value of serum analyses of S100β protein in malignant melanoma
10. Prognostic significance of serum S100β detection compared with routine blood parameters in advanced metastatic melanoma patients
11. S100β, MIA and LDH discriminate progressive from non-progressive AJCC stage IV melanoma disease
12. Predictive value of serum S100β for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy
13. Melanoma-inhibitory activity protein concentrations in blood of melanoma patients treated with immunotherapy
14. Comparing the areas under two or more correlated receiver operating characteristic curves, a nonparametric approach
15. A note on a general definition of the coefficient of determination
16. Classification and regression trees (CART) used for the exploration of prognostic factors measured on different scales
17. Predictors of clinical response to interleukin-2-based immunotherapy in melanoma patients: A French multiinstitutional study
18. Serum level of interleukin 6 as a prognostic factor in metastatic renal cell carcinoma
19. Metabolic disturbance and sensitivity to endotoxin in patients with advanced cancer, relationship to lymphocyte reactivity, tumour necrosis factor production and survival
20. Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer
21. The acute phase response and C-reactive protein
22. MIA (melanoma inhibitory activity), a potential serum marker for rheumatoid arthritis